The new AI solution is intended for the early identification of sepsis. Credit: Analysis Studio / Shutterstock.com.

Mednition has received the US Food and Drug Administration (FDA) breakthrough device designation for its artificial intelligence (AI)-powered solution, KATE Sepsis.

The new solution is intended for the early identification of sepsis, the leading cause of death, readmissions and hospitalisations in US hospitals.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Mednition CEO Steven Reilly said: “This recognition underscores our commitment to advancing equitable care, improving patient outcomes and reducing risk for patients.

“We believe every second counts in the fight against sepsis. KATE Sepsis represents a significant leap forward in detecting this life-threatening condition earlier and enabling clinicians to provide more effective and timely treatment.”

KATE Sepsis demonstrated its ability in early sepsis detection, exceeding standard screening protocols by up to 118% at Emergency Department Triage.

See Also:

Its predictions have a higher sensitivity, showing an 80% improvement for severe sepsis, 74% for sepsis and 118% for septic shock compared to the standard screening algorithm.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This sensitivity enhancement is attained without a decrease in specificity, which is 95% for the AI-powered solution.

Mednition president Christian Reilly said: “Expanding our KATE AI platform, already proven effective in detecting high-risk patients, to now also signal risk of sepsis is a natural extension and perfect use case for our clinical AI.”

Mednition combines the strength of EHR-integrated AI and clinical expertise to address key challenges in the healthcare industry.

The company has designed the KATE AI solution to lower clinical risk, support emergency nurses and enhance the quality of care.